Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 164 entries
Sorted by: Best Match Show Resources per page
Cost-Effectiveness and Cost-Utility of Granulocyte Colony-Stimulating Factors in the Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia (FN) in Breast Cancer Patients in Greece: A Comparative Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Kourlaba G, Palaka E, Papagiannopoulou V, Maniadakis N.
PMID: 27202253
Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2269. Epub 2014 Oct 26.

No abstract available.

Cite
Kourlaba G, Palaka E, Papagiannopoulou V, et al. Cost-Effectiveness and Cost-Utility of Granulocyte Colony-Stimulating Factors in the Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia (FN) in Breast Cancer Patients in Greece: A Comparative Analysis. Value Health. 2014;17(7):A633doi: 10.1016/j.jval.2014.08.2269.
Kourlaba, G., Palaka, E., Papagiannopoulou, V., & Maniadakis, N. (2014). Cost-Effectiveness and Cost-Utility of Granulocyte Colony-Stimulating Factors in the Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia (FN) in Breast Cancer Patients in Greece: A Comparative Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A633. https://doi.org/10.1016/j.jval.2014.08.2269
Kourlaba, G, et al. "Cost-Effectiveness and Cost-Utility of Granulocyte Colony-Stimulating Factors in the Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia (FN) in Breast Cancer Patients in Greece: A Comparative Analysis." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A633. doi: https://doi.org/10.1016/j.jval.2014.08.2269
Kourlaba G, Palaka E, Papagiannopoulou V, Maniadakis N. Cost-Effectiveness and Cost-Utility of Granulocyte Colony-Stimulating Factors in the Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia (FN) in Breast Cancer Patients in Greece: A Comparative Analysis. Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2269. Epub 2014 Oct 26. PMID: 27202253.
Copy Download .nbib Format: NLM
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.

Biologics : targets & therapy

Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P.
PMID: 26858523
Biologics. 2016 Jan 22;10:1-8. doi: 10.2147/BTT.S58597. eCollection 2016.

Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence...

Cite
Guariglia R, Martorelli MC, Lerose R, et al. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics. 2016;10:1-8doi: 10.2147/BTT.S58597.
Guariglia, R., Martorelli, M. C., Lerose, R., Telesca, D., Milella, M. R., & Musto, P. (2016). Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics : targets & therapy, 101-8. https://doi.org/10.2147/BTT.S58597
Guariglia, Roberto, et al. "Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients." Biologics : targets & therapy vol. 10 (2016): 1-8. doi: https://doi.org/10.2147/BTT.S58597
Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics. 2016 Jan 22;10:1-8. doi: 10.2147/BTT.S58597. eCollection 2016. PMID: 26858523; PMCID: PMC4730998.
Copy Download .nbib Format: NLM
Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.

Current oncology (Toronto, Ont.)

Altwairgi AK, Hopman WM, Mates M.
PMID: 23737687
Curr Oncol. 2013 Jun;20(3):e171-9. doi: 10.3747/co.20.1306.

BACKGROUND: Primary prophylaxis with granulocyte colony-stimulating factors (pp-g-csf) is recommended in patients undergoing chemotherapy carrying a febrile neutropenia (fn) risk of 20% or more. In the present study, we examined clinical practice patterns and the impact of pp-g-csf on...

Cite
Altwairgi AK, Hopman WM, Mates M. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol. 2013;20(3):e171-9doi: 10.3747/co.20.1306.
Altwairgi, A. K., Hopman, W. M., & Mates, M. (2013). Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Current oncology (Toronto, Ont.), 20(3), e171-9. https://doi.org/10.3747/co.20.1306
Altwairgi, A K, et al. "Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia." Current oncology (Toronto, Ont.) vol. 20,3 (2013): e171-9. doi: https://doi.org/10.3747/co.20.1306
Altwairgi AK, Hopman WM, Mates M. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol. 2013 Jun;20(3):e171-9. doi: 10.3747/co.20.1306. PMID: 23737687; PMCID: PMC3671024.
Copy Download .nbib Format: NLM
Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Geissler RG, Ganser A.
PMID: 18020588
BioDrugs. 1998 Aug;10(2):97-109. doi: 10.2165/00063030-199810020-00002.

Myelodysplastic syndromes (MDS) are clonal disorders of haemopoietic stem cells which are characterised by peripheral cytopenia and, usually, by an increased bone marrow cellularity. Transfusions of red blood cells and platelets comprise the basis of supportive care for anaemia...

Cite
Geissler RG, Ganser A. Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. BioDrugs. 1998;10(2):97-109doi: 10.2165/00063030-199810020-00002.
Geissler, R. G., & Ganser, A. (1998). Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 10(2), 97-109. https://doi.org/10.2165/00063030-199810020-00002
Geissler, R G, and Ganser, A. "Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 10,2 (1998): 97-109. doi: https://doi.org/10.2165/00063030-199810020-00002
Geissler RG, Ganser A. Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. BioDrugs. 1998 Aug;10(2):97-109. doi: 10.2165/00063030-199810020-00002. PMID: 18020588.
Copy Download .nbib Format: NLM
Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma.

Advances in hematology

Vakkalanka B, Link BK.
PMID: 21687649
Adv Hematol. 2011;2011:656013. doi: 10.1155/2011/656013. Epub 2011 May 02.

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter...

Cite
Vakkalanka B, Link BK. Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Adv Hematol. 2011;2011:656013doi: 10.1155/2011/656013.
Vakkalanka, B., & Link, B. K. (2011). Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Advances in hematology, 2011656013. https://doi.org/10.1155/2011/656013
Vakkalanka, Bhanu, and Link, Brian K. "Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma." Advances in hematology vol. 2011 (2011): 656013. doi: https://doi.org/10.1155/2011/656013
Vakkalanka B, Link BK. Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Adv Hematol. 2011;2011:656013. doi: 10.1155/2011/656013. Epub 2011 May 02. PMID: 21687649; PMCID: PMC3112508.
Copy Download .nbib Format: NLM
Canadian supportive care recommendations for the management of neutropenia in patients with cancer.

Current oncology (Toronto, Ont.)

Kouroukis CT, Chia S, Verma S, Robson D, Desbiens C, Cripps C, Mikhael J.
PMID: 18317581
Curr Oncol. 2008 Jan;15(1):9-23. doi: 10.3747/co.2008.198.

Hematologic toxicities of cancer chemotherapy are common and often limit the ability to provide treatment in a timely and dose-intensive manner. These limitations may be of utmost importance in the adjuvant and curative intent settings. Hematologic toxicities may result...

Cite
Kouroukis CT, Chia S, Verma S, et al. Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol. 2008;15(1):9-23doi: 10.3747/co.2008.198.
Kouroukis, C. T., Chia, S., Verma, S., Robson, D., Desbiens, C., Cripps, C., & Mikhael, J. (2008). Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Current oncology (Toronto, Ont.), 15(1), 9-23. https://doi.org/10.3747/co.2008.198
Kouroukis, C T, et al. "Canadian supportive care recommendations for the management of neutropenia in patients with cancer." Current oncology (Toronto, Ont.) vol. 15,1 (2008): 9-23. doi: https://doi.org/10.3747/co.2008.198
Kouroukis CT, Chia S, Verma S, Robson D, Desbiens C, Cripps C, Mikhael J. Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol. 2008 Jan;15(1):9-23. doi: 10.3747/co.2008.198. PMID: 18317581; PMCID: PMC2259432.
Copy Download .nbib Format: NLM
Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.

American health & drug benefits

Force RW, Pugmire BA, Culbertson VL.
PMID: 25126321
Am Health Drug Benefits. 2010 Jul;3(4):276-84.

BACKGROUND: It has been estimated that more than $8 billion is spent annually on the management of breast cancer in the United States. The taxane chemotherapeutic agents are cornerstones in the treatment of breast cancer, yet no study has...

Cite
Force RW, Pugmire BA, Culbertson VL. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis. Am Health Drug Benefits. 2010;3(4):276-84
Force, R. W., Pugmire, B. A., & Culbertson, V. L. (2010). Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis. American health & drug benefits, 3(4), 276-84.
Force, Rex W, et al. "Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis." American health & drug benefits vol. 3,4 (2010): 276-84.
Force RW, Pugmire BA, Culbertson VL. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis. Am Health Drug Benefits. 2010 Jul;3(4):276-84. PMID: 25126321; PMCID: PMC4106600.
Copy Download .nbib Format: NLM
Haemopoietic growth factors: their role in cell development and their clinical use.

Cytotechnology

Testa NG, Dexter TM.
PMID: 22358868
Cytotechnology. 1989 Dec;2(4):259-67. doi: 10.1007/BF00364992.

Mature blood cells are derived from haemopoietic stem cells which grow and proliferate to give rise to progenitor cells more restricted in their proliferation and differentiation capacity. These in turn give rise to cells belonging to any of the...

Cite
Testa NG, Dexter TM. Haemopoietic growth factors: their role in cell development and their clinical use. Cytotechnology. 1989;2(4):259-67doi: 10.1007/BF00364992.
Testa, N. G., & Dexter, T. M. (1989). Haemopoietic growth factors: their role in cell development and their clinical use. Cytotechnology, 2(4), 259-67. https://doi.org/10.1007/BF00364992
Testa, N G, and Dexter, T M. "Haemopoietic growth factors: their role in cell development and their clinical use." Cytotechnology vol. 2,4 (1989): 259-67. doi: https://doi.org/10.1007/BF00364992
Testa NG, Dexter TM. Haemopoietic growth factors: their role in cell development and their clinical use. Cytotechnology. 1989 Dec;2(4):259-67. doi: 10.1007/BF00364992. PMID: 22358868.
Copy Download .nbib Format: NLM
Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience.

Revista brasileira de hematologia e hemoterapia

Gabús R, Borelli G, Ferrando M, Bódega E, Citrín E, Jiménez CO, Alvarez R.
PMID: 23049356
Rev Bras Hematol Hemoter. 2011;33(6):410-6. doi: 10.5581/1516-8484.20110115.

BACKGROUND: In 2006 the Hematology Service of Hospital Maciel published its experience with peripheral blood progenitor cell harvesting for autologous stem cell transplantation using Filgen JP (Clausen Filgrastim). After mobilization with a mean filgrastim dose of 78 mcg/Kg, 4.7...

Cite
Gabús R, Borelli G, Ferrando M, et al. Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience. Rev Bras Hematol Hemoter. 2011;33(6):410-6doi: 10.5581/1516-8484.20110115.
Gabús, R., Borelli, G., Ferrando, M., Bódega, E., Citrín, E., Jiménez, C. O., & Alvarez, R. (2011). Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience. Revista brasileira de hematologia e hemoterapia, 33(6), 410-6. https://doi.org/10.5581/1516-8484.20110115
Gabús, Raul, et al. "Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience." Revista brasileira de hematologia e hemoterapia vol. 33,6 (2011): 410-6. doi: https://doi.org/10.5581/1516-8484.20110115
Gabús R, Borelli G, Ferrando M, Bódega E, Citrín E, Jiménez CO, Alvarez R. Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience. Rev Bras Hematol Hemoter. 2011;33(6):410-6. doi: 10.5581/1516-8484.20110115. PMID: 23049356; PMCID: PMC3459372.
Copy Download .nbib Format: NLM
Cellular response within the periodontal ligament on application of orthodontic forces.

Journal of Indian Society of Periodontology

Meeran NA.
PMID: 23633766
J Indian Soc Periodontol. 2013 Jan;17(1):16-20. doi: 10.4103/0972-124X.107468.

During application of controlled orthodontic force on teeth, remodeling of the periodontal ligament (PDL) and the alveolar bone takes place. Orthodontic forces induce a multifaceted bone remodeling response. Osteoclasts responsible for bone resorption are mainly derived from the macrophages...

Cite
Meeran NA. Cellular response within the periodontal ligament on application of orthodontic forces. J Indian Soc Periodontol. 2013;17(1):16-20doi: 10.4103/0972-124X.107468.
Meeran, N. A. (2013). Cellular response within the periodontal ligament on application of orthodontic forces. Journal of Indian Society of Periodontology, 17(1), 16-20. https://doi.org/10.4103/0972-124X.107468
Meeran, Nazeer Ahmed. "Cellular response within the periodontal ligament on application of orthodontic forces." Journal of Indian Society of Periodontology vol. 17,1 (2013): 16-20. doi: https://doi.org/10.4103/0972-124X.107468
Meeran NA. Cellular response within the periodontal ligament on application of orthodontic forces. J Indian Soc Periodontol. 2013 Jan;17(1):16-20. doi: 10.4103/0972-124X.107468. PMID: 23633766; PMCID: PMC3636936.
Copy Download .nbib Format: NLM
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.

Journal of pharmaceutical health care and sciences

Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K.
PMID: 29375887
J Pharm Health Care Sci. 2018 Jan 17;4:2. doi: 10.1186/s40780-018-0098-y. eCollection 2018.

BACKGROUND: Clinical practice guidelines should be user-friendly and confirming their penetration rate and compliance are critical.METHODS: We conducted a nationwide web-based questionnaire survey among pharmacists regarding the 2013 guidelines for the appropriate use of granulocyte-colony stimulating factors (GRESULTS: A...

Cite
Sasaki T, Kato Y, Sato A, et al. A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. J Pharm Health Care Sci. 2018;4:2doi: 10.1186/s40780-018-0098-y.
Sasaki, T., Kato, Y., Sato, A., Usui, N., Baba, E., Takano, T., Susumu, N., Ohnishi, K., Nishimoto, H., & Kiura, K. (2018). A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. Journal of pharmaceutical health care and sciences, 42. https://doi.org/10.1186/s40780-018-0098-y
Sasaki, Tetsuya, et al. "A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors." Journal of pharmaceutical health care and sciences vol. 4 (2018): 2. doi: https://doi.org/10.1186/s40780-018-0098-y
Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K. A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. J Pharm Health Care Sci. 2018 Jan 17;4:2. doi: 10.1186/s40780-018-0098-y. eCollection 2018. PMID: 29375887; PMCID: PMC5772721.
Copy Download .nbib Format: NLM
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar.

ClinicoEconomics and outcomes research : CEOR

Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S.
PMID: 30214262
Clinicoecon Outcomes Res. 2018 Sep 03;10:493-500. doi: 10.2147/CEOR.S168298. eCollection 2018.

BACKGROUND: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. Data comparing biosimilar filgrastim-sndz with reference filgrastim (filgrastim-ref) are limited outside of clinical trials in the US.OBJECTIVE:...

Cite
Schwartzberg LS, Lal LS, Balu S, et al. Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. Clinicoecon Outcomes Res. 2018;10:493-500doi: 10.2147/CEOR.S168298.
Schwartzberg, L. S., Lal, L. S., Balu, S., Campbell, K., Brekke, L., Elliott, C., & Korrer, S. (2018). Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. ClinicoEconomics and outcomes research : CEOR, 10493-500. https://doi.org/10.2147/CEOR.S168298
Schwartzberg, Lee S, et al. "Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar." ClinicoEconomics and outcomes research : CEOR vol. 10 (2018): 493-500. doi: https://doi.org/10.2147/CEOR.S168298
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S. Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. Clinicoecon Outcomes Res. 2018 Sep 03;10:493-500. doi: 10.2147/CEOR.S168298. eCollection 2018. PMID: 30214262; PMCID: PMC6126503.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 164 entries